Emergent BioSolutions (EBS) Tops Q3 EPS by 32c; Says FY16 Outlook Still Postponed
Get Alerts EBS Hot Sheet
Price: $2.04 +9.68%
Revenue Growth %: +12.3%
Financial Fact:
Interest income: 358K
Today's EPS Names:
MAXN, CSTR, ACU, More
Revenue Growth %: +12.3%
Financial Fact:
Interest income: 358K
Today's EPS Names:
MAXN, CSTR, ACU, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q3 EPS of $0.58, $0.32 better than the analyst estimate of $0.26. Revenue for the quarter came in at $142.9 million versus the consensus estimate of $112.3 million.
The Company continues to postpone its financial guidance for 2016 until the CDC follow-on BioThrax® procurement contract has been finalized.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- American Express (AXP) down despite beating Q1 estimates on top and bottom lines
- Parke Bancorp (PKBK) Reports Q1 EPS of $0.51
- Vail Resorts (MTN) Reports Certain Ski Season Metrics for the Season-to-Date Period Ended April 14
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!